gabexate has been researched along with Body Weight in 16 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An experimental model of chronic pancreatitis was induced by a retrograde injection of a viscous solution consisting of zein-oleic acid-linoleic acid (0." | 7.70 | Pathophysiologic studies of experimental chronic pancreatitis in rats induced by injection of zein-oleic acid-linoleic acid solution into the pancreatic duct. ( Kashima, K; Kataoka, K; Sakagami, J; Sasaki, T; Yorizumi, H, 1998) |
| "The systemic effects of epidermal growth factor (EGF) ointment containing nafamostat (NM), gabexate, or gelatin was studied in rats with burns or open wounds." | 7.68 | Systemic effects of epidermal growth factor (EGF) ointment containing protease inhibitor or gelatin in rats with burns or open wounds. ( Fuwa, T; Iwakawa, S; Kiyohara, Y; Komada, F; Okumura, K, 1993) |
| "Camostat-fed rats gained less weight or lost weight, although they consumed more food than the control rat when food intake was adjusted for body weight." | 3.73 | Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats. ( Jia, D; Otsuki, M; Taguchi, M, 2005) |
| "An experimental model of chronic pancreatitis was induced by a retrograde injection of a viscous solution consisting of zein-oleic acid-linoleic acid (0." | 3.70 | Pathophysiologic studies of experimental chronic pancreatitis in rats induced by injection of zein-oleic acid-linoleic acid solution into the pancreatic duct. ( Kashima, K; Kataoka, K; Sakagami, J; Sasaki, T; Yorizumi, H, 1998) |
| "The systemic effects of epidermal growth factor (EGF) ointment containing nafamostat (NM), gabexate, or gelatin was studied in rats with burns or open wounds." | 3.68 | Systemic effects of epidermal growth factor (EGF) ointment containing protease inhibitor or gelatin in rats with burns or open wounds. ( Fuwa, T; Iwakawa, S; Kiyohara, Y; Komada, F; Okumura, K, 1993) |
| "The effect of long-term oral synthetic protease inhibitor (FOY 305) administration on fasting blood sugar (FBS), body weight, glucose tolerance, plasma insulin and glucagon levels, pancreatic insulin and glucagon contents, hepatic enzyme activities, and plasma lipids in normal and streptozotocin (STZ)-induced diabetic rats was studied." | 3.67 | [The effect of oral synthetic protease inhibitor (FOY 305) on endocrine pancreas and carbohydrate and lipid metabolism in normal and streptozotocin-induced diabetic rats]. ( Eto, M; Futaki, G; Ishii, K; Kagaya, T; Oyama, K; Saito, T; Sakai, Y; Takebe, T; Watanabe, K; Yoshida, S, 1984) |
| "The effects of chronic oral treatment of rats with 400 mg/kg body weight camostat, a synthetic protease inhibitor, on weight gain and both pancreatic exocrine and endocrine secretion were studied and compared with pair-fed controls." | 3.67 | Effects of camostat, a synthetic protease inhibitor, on endocrine and exocrine pancreas of the rat. ( Alfen, R; Ehlers, J; Goebell, H; Jäger, M; Müller, MK; Plümpe, H, 1988) |
| "Chronic oral administration of camostate, a specific serine protease inhibitor, is known to induce pancreas hypertrophy in rats." | 3.67 | [Effect of a specific serine protease inhibitor on the rat pancreas. II. Influence of camostate on the endocrine pancreas]. ( Creutzfeldt, W; Göke, B; Lankisch, PG; Siegel, EG; Stöckmann, F, 1985) |
| " This drug at a dosage of 10 mg/kg or 20 mg/kg was administered by ip injection to 20 mice each harboring a solitary tumor twice daily for 10 weeks." | 1.26 | Inhibition of growth of 3-methylcholanthrene-induced mouse skin tumor by protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate. ( Ohkoshi, M, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (43.75) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, D | 1 |
| Taguchi, M | 1 |
| Otsuki, M | 1 |
| McLaughlin, CL | 1 |
| Peikin, SR | 1 |
| Baile, CA | 1 |
| Eto, M | 1 |
| Watanabe, K | 1 |
| Kagaya, T | 1 |
| Sakai, Y | 1 |
| Yoshida, S | 1 |
| Oyama, K | 1 |
| Futaki, G | 1 |
| Saito, T | 1 |
| Takebe, T | 1 |
| Ishii, K | 1 |
| Baba, N | 1 |
| Suzuki, T | 1 |
| Tobe, T | 1 |
| Ohkoshi, M | 1 |
| Oikawa, I | 1 |
| Hirata, K | 1 |
| Mikami, T | 1 |
| Denno, R | 1 |
| Kiyohara, Y | 1 |
| Komada, F | 1 |
| Iwakawa, S | 1 |
| Fuwa, T | 1 |
| Okumura, K | 1 |
| Ge, YC | 1 |
| Morgan, RG | 1 |
| Kogire, M | 1 |
| Inoue, K | 1 |
| Gu, Y | 1 |
| Uchida, K | 1 |
| Imamura, M | 1 |
| Kataoka, K | 1 |
| Sasaki, T | 1 |
| Yorizumi, H | 1 |
| Sakagami, J | 1 |
| Kashima, K | 1 |
| Kawanami, T | 1 |
| Suzuki, S | 1 |
| Yoshida, Y | 1 |
| Kanai, S | 1 |
| Takata, Y | 1 |
| Shimazoe, T | 1 |
| Watanabe, S | 1 |
| Funakoshi, A | 1 |
| Miyasaka, K | 2 |
| Voigt, JP | 1 |
| Wenz, D | 1 |
| Voits, M | 1 |
| Fink, H | 1 |
| Kamiyasu, K | 1 |
| Awata, H | 1 |
| Inoshiri, S | 1 |
| Doi, A | 1 |
| Omawari, N | 1 |
| Okegawa, T | 1 |
| Kawasaki, A | 1 |
| Shinomiya, K | 1 |
| Tanaka, M | 1 |
| Suzuki, Y | 1 |
| Müller, MK | 1 |
| Goebell, H | 1 |
| Alfen, R | 1 |
| Ehlers, J | 1 |
| Jäger, M | 1 |
| Plümpe, H | 1 |
| Nakamura, R | 1 |
| Kitani, K | 1 |
| Göke, B | 1 |
| Siegel, EG | 1 |
| Stöckmann, F | 1 |
| Lankisch, PG | 1 |
| Creutzfeldt, W | 1 |
16 other studies available for gabexate and Body Weight
| Article | Year |
|---|---|
Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Eating; Esters; Fast | 2005 |
Decreased pancreatic CCK receptor binding and CCK-stimulated amylase release in Zucker obese rats.
Topics: Amylases; Animals; Body Weight; Carbachol; Culture Techniques; DNA; Dose-Response Relationship, Drug | 1984 |
[The effect of oral synthetic protease inhibitor (FOY 305) on endocrine pancreas and carbohydrate and lipid metabolism in normal and streptozotocin-induced diabetic rats].
Topics: Animals; Blood Glucose; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Ester | 1984 |
Effects of trypsin inhibitor on the remnant pancreas after 85 percent pancreatectomy in rats.
Topics: 4-Aminobenzoic Acid; Animals; Blood Glucose; Body Weight; Esters; Gabexate; Guanidines; Insulin; Isl | 1984 |
Inhibition of growth of 3-methylcholanthrene-induced mouse skin tumor by protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate.
Topics: Animals; Body Weight; Carcinoma, Squamous Cell; Cell Division; Drug Evaluation, Preclinical; Esters; | 1981 |
An experimental study on the effects of selected drugs on pancreatic regeneration after partial pancreatectomy.
Topics: Amylases; Animals; Body Weight; Ceruletide; DNA; Esters; Gabexate; Guanidines; Hydrocortisone; Male; | 1993 |
Systemic effects of epidermal growth factor (EGF) ointment containing protease inhibitor or gelatin in rats with burns or open wounds.
Topics: Animals; Aspartate Aminotransferases; Benzamidines; Body Weight; Burns; Drug Interactions; Drug Syne | 1993 |
The effect of trypsin inhibitor on the pancreas and small intestine of mice.
Topics: Animals; Body Weight; Duodenum; Esters; Gabexate; Glycine max; Guanidines; Intestine, Small; Male; M | 1993 |
Chronic effects of camostate on growth and endocrine function of the pancreas in streptozotocin-induced diabetic rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Esters; Gabexate; Guanidines; Hyperplasia; Hy | 1993 |
Pathophysiologic studies of experimental chronic pancreatitis in rats induced by injection of zein-oleic acid-linoleic acid solution into the pancreatic duct.
Topics: Amylases; Animals; Blood Glucose; Body Weight; Chronic Disease; Disease Models, Animal; Esters; Gabe | 1998 |
Different effects of trypsin inhibitors on intestinal gene expression of secretin and on pancreatic bicarbonate secretion in CCK-A-receptor-deficient rats.
Topics: Allylglycine; Animals; Benzamidines; Bicarbonates; Blotting, Northern; Body Weight; Cholecystokinin; | 1999 |
Does increased endogenous CCK interact with serotonin to reduce food intake in rats?
Topics: Animals; Anorexia; Body Weight; Cholecystokinin; Dose-Response Relationship, Drug; Drug Interactions | 2000 |
[Effects of FOY-305 on post-operative reflux esophagitis in rats (I). Effects of FOY-305 on reflux esophagitis after total gastrectomy in rats].
Topics: Alginates; Animals; Body Weight; Cimetidine; Disease Models, Animal; Esophagitis, Peptic; Esters; Ga | 1991 |
Effects of camostat, a synthetic protease inhibitor, on endocrine and exocrine pancreas of the rat.
Topics: Amylases; Animals; Body Weight; Chromatography, High Pressure Liquid; Chymotrypsin; Esters; Gabexate | 1988 |
Effects of trypsin inhibitor (camostate) on pancreas and CCK release in young and old female rats.
Topics: Aging; Animals; Body Weight; Cholecystokinin; Dose-Response Relationship, Drug; Esters; Female; Gabe | 1989 |
[Effect of a specific serine protease inhibitor on the rat pancreas. II. Influence of camostate on the endocrine pancreas].
Topics: Administration, Oral; Animals; Body Weight; Esters; Gabexate; Guanidines; Hypertrophy; Insulin; Insu | 1985 |